Asset Details
Do you wish to reserve the book?
Neutrophil gelatinase‐associated lipocalin: An early biomarker for predicting acute kidney injury and severity in patients with acute pancreatitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neutrophil gelatinase‐associated lipocalin: An early biomarker for predicting acute kidney injury and severity in patients with acute pancreatitis
Do you wish to request the book?
Neutrophil gelatinase‐associated lipocalin: An early biomarker for predicting acute kidney injury and severity in patients with acute pancreatitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Neutrophil gelatinase‐associated lipocalin: An early biomarker for predicting acute kidney injury and severity in patients with acute pancreatitis
2019
Overview
Acute kidney injury (AKI) in severe acute pancreatitis (SAP) has a high mortality rate. Traditionally used serum creatinine is an insensitive biomarker for the early detection of AKI. We aimed to study the role of plasma and urinary neutrophil gelatinase-associated lipocalin (NGAL) in predicting AKI and a severe course in patients with acute pancreatitis (AP).
Consecutive patients of AP who presented within 72 h of symptom onset and age- and gender-matched healthy controls were included. Urinary and serum NGAL levels [enzyme-linked immunosorbent assay (ELISA)] were evaluated within 24 h of and 72 h after admission and once in controls. Urine and serum NGAL levels were correlated with development of AKI, severity, and outcomes of AP.
Fifty patients with AP and 30 controls were enrolled. The mean serum and urine NGAL levels in patients on day 1 were significantly higher than the serum and urine NGAL levels in controls (
< 0.001). After excluding patients with AKI on day 1 (
= 10), both serum and urinary NGAL levels on days 1 and 3 were significantly higher in patients who subsequently developed AKI (
= 11) compared to those who did not (
= 29) (
= 0.02, 0.01 and
< 0.001, 0.03). A urinary NGAL level of 221.03 ng/mL on day 1 predicted AKI with a sensitivity and specificity of 82 and 80%, respectively (AUC = 0.9). Mean serum and urinary NGAL levels on day 1 were significantly elevated in patients with SAP compared to those without SAP (
= 0.04 and <0.001).
NGAL levels in urine and serum can predict severity of AP and development of AKI.
